Total
0
Shares
Levitee Labs - CEO, Pouya Farmand.
CEO, Pouya Farmand.
Source: Levitee Labs.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services
  • Adracare, a Well Health Technologies company, has developed a digital technology platform that allows clinics to better engage with their patients
  • This platform will also serve as an opportunity for Levitee Labs to scale psychedelic therapies to various communities across Canada
  • Levitee Labs is a functional mushrooms company focused on the development and sale of high potency mushroom extract nutraceuticals and supplies and equipment for mushroom cultivation
  • Shares in Levitee Labs Inc. (LVT) are steady, trading at $0.49 per share

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

Adracare, a Well Health Technologies company, has developed a digital technology platform that allows clinics to better engage with their patients.

Levitee Labs is excited to be joining the WELL Health network for the opportunity to further bolster its healthcare and wellness assets.

The partnership will provide Levitee Labs access to WELL’s comprehensive end-to-end practice management tools including a world-class telemedicine platform.

Pouya Farmand, CEO of Levitee Labs, commented on the partnership.

“We believe Adracare is a world-class partner with which to build out a telemedicine and integrated technology platform, with the goal of delivering psychedelic-inspired medicines and experimental therapies combined with digital therapeutics,” said Mr. Farmand.

This platform will also serve as an opportunity for Levitee Labs to scale psychedelic therapies to various communities across Canada, where there is a critical shortage of in-person care providers.

“By introducing psychedelic medicine services into traditional healthcare infrastructure,” said Mr. Farmand, “Levitee Labs will be able to precisely gauge the impact of psychedelic-assisted therapies on patients.”

By partnering with Adracare, Levitee Labs is now equipped with a telehealth strategy and platform to provide care to more patients and cover a variety of multidisciplinary addiction and mental health services, including one-on-one counselling, group therapy, consultations, and psychedelic treatments.

Shervin Bakhtiari, GM of Digital Health Apps at WELL, commented,

“We are delighted to partner with Levitee Labs, to empower them with a leading digital platform to support their growth.”

Levitee Labs is a functional mushrooms company focused on the development and sale of high potency mushroom extract nutraceuticals and supplies and equipment for mushroom cultivation.

Shares in Levitee Labs Inc. (LVT) are steady, trading at $0.49 per share as of 12:39 pm ET.

More From The Market Herald
Pluribus Technologies - CEO, Richard Adair.

" Pluribus Technologies completes equity financing

Pluribus Technologies has completed a C$25M equity financing.
The Market Herald Video

" LUXXFOLIO Holdings (CSE:LUXX) provides operational update

LUXXFOLIO Holdings’ (LUXX) November updates includes record mining revenues of approximately $1.8 million and monthly rewards of 23.5 Bitcoin.
Victory Square Technologies - CEO, Shafin Diamond Tejani

" Victory Square Technologies (CSE:VST) to issue the second tranche of dividend

Victory Square (VST) will issue the second tranche of its special dividend of common shares of portfolio company Fantasy 360 Technologies in December

" Upco International (CSE:UPCO) announces Q3 2021 interim financial results

Upco International (UPCO) focused on growing its wholesale telecom business in the third quarter, resulting in higher revenue.